CLARITIN LIQUID CAPSULES

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

LORATADINE

Beszerezhető a:

BAYER INC

ATC-kód:

R06AX13

INN (nemzetközi neve):

LORATADINE

Adagolás:

10MG

Gyógyszerészeti forma:

CAPSULE

Összetétel:

LORATADINE 10MG

Az alkalmazás módja:

ORAL

db csomag:

24/36/84

Recept típusa:

OTC

Terápiás terület:

SECOND GENERATION ANTIHISTAMINES

Termék összefoglaló:

Active ingredient group (AIG) number: 0120416001; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2014-12-05

Termékjellemzők

PRODUCT MONOGRAPH
CLARITIN
® LIQUID CAPSULES LORATADINE CAPSULES, 10 MG
HISTAMINE H
1
RECEPTOR ANTAGONIST
Bayer Inc.
DATE OF PREPARATION:
2920 Matheson Blvd. E
May 10
th
, 2019
Mississauga, ON
L4W 5R6
Control #: 225631
® TM see www.bayer.ca/tm-mc
_ _
_CLARITIN LIQUID CAPSULES _
_Page 2 of 22_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
………………………………….…...
3
SUMMARY PRODUCT INFORMATION
...........................................................................
3
INDICATIONS AND CLINICAL
USE.................................................................................
3
CONTRAINDICATIONS
......................................................................................................
3
WARNINGS AND PRECAUTIONS
....................................................................................
3
ADVERSE REACTIONS
......................................................................................................
4
DRUG INTERACTIONS
.......................................................................................................
6
DOSAGE AND ADMINISTRATION
...................................................................................
7
OVERDOSAGE
.....................................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 7
STORAGE AND STABILITY
..............................................................................................
8
SPECIAL HANDLING INSTRUCTIONS
............................................................................
8
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 9
PART II: SCIENTIFIC INFORMATION
…………………………………………………….
. 10
PHARMACEUTICAL INFORMATION
............................................................................
10
CLINICAL
TRIALS...........................................................